Introduction {#S1}
============

Spondyloenchondrodysplasia (SPENCD, OMIM \#607944) is a rare autosomal recessive skeletal dysplasia characterized by vertebral dysplasia and enchondroma-like radiolucent metaphyseal lesions of the long bones ([@B1]). Affected individuals manifest with short-trunked short stature. In addition, they show a variety of extraskeletal abnormalities, including neurological symptoms (intracranial calcification, developmental delay, spasticity, clumsy movements), and immune dysregulation (autoimmune diseases, immunodeficiency) ([@B2]--[@B10]). Recently, two groups reported biallelic hypomorphic mutations in the Acid Phosphatase 5, Tartrate Resistant (*ACP5*) gene as a genetic cause of SPENCD ([@B11], [@B12]). *ACP5* encodes tartrate-resistant acid phosphatase (TRAP). TRAP deficiency increases levels of phosphorylated osteopontin, which causes dysregulated endochondral ossification and other manifestations, and also an interferon (INF) signature (increased expression of type I INF regulated genes) leading to extraskeletal complications ([@B11]--[@B13]). Very little is documented concerning medical intervention for short stature and INF signature in SPENCD. Some SPENCD reports have mentioned attempts of growth hormone (GH) therapy, but the effect of GH has not been fully detailed ([@B4], [@B10]).

We report here an affected Japanese boy with novel compound heterozygous *ACP5* mutations, who had the typical skeletal phenotype of SPENCD, brain calcifications, absence of TRAP activity, and laboratory findings of an INF signature, but no immunodeficiency or autoimmune disorders. He had developed short stature in early childhood, leading to a diagnosis of partial GH deficiency (GHD) and introduction of GH therapy prior to the definitive diagnosis of SPENCD. Interestingly, his growth velocity was significantly accelerated in response to GH treatment.

Case Report {#S2}
===========

The patient is a 6-year-old Japanese boy who was born to non-consanguineous healthy parents. The patient's mid-parental target height was 180 cm (final height of his father and mother was 177 and 170 cm, respectively). His older brother was healthy (Figure [1](#F1){ref-type="fig"}A). He was born at term after an uncomplicated pregnancy and delivery. Birth weight was 3,055 g (−0.64 SD), length 51.5 cm (+1.06 SD), and head circumference 34.0 cm (+0.40 SD). At 19 months, he was referred to us because of his inability to walk unaided. At that time brain MRI yielded a normal finding. He entered a rehabilitation program that improved his ambulation. His linear growth started to slow down from 5 months of age. At 38 months of age his height was 84.5 cm (−2.89 SD) (Figure [1](#F1){ref-type="fig"}B). Thyroid function was normal (TSH 4.520 μU/mL, FT4 1.06 ng/dL). The level of baseline insulin-like growth factor I (IGF-I) was low (18 ng/mL). These clinical manifestations and results of a GH stimulation test led to the diagnosis of partial GHD (peak GH response to arginine was 4.60 ng/mL and to clonidine was 2.41 ng/mL; the cut-off point was \<6 ng/mL to define partial GHD and \<3 ng/mL to define severe GHD) (Table S1 in Supplementary Material). GH therapy (0.175 mg/kg/week) was introduced, and it significantly accelerated his growth velocity (Figure [1](#F1){ref-type="fig"}B).

![**(A)** Family tree. **(B)** Growth curve. At age 38 months, the patient's height was 84.5 cm (−2.89 SD) and growth hormone (GH) therapy was commenced. The patient's growth curve significantly improved with GH treatment over time. Height curve; red circles, weight curve; blue squares.](fendo-08-00157-g001){#F1}

At 6 years of age, he presented with painful knee joints. Height was 109.5 cm (−1.04 SD), and arm span was 111 cm. Facial features and body proportion were normal (Figure [2](#F2){ref-type="fig"}A). Development (language and cognitive skills, and fine and gross motor skills) was appropriate for his age, other than some clumsiness in motion. A radiograph of the knee showed mild metaphyseal dysplasia of the knee (shaved contour and marginal spur in the distal femoral metaphyses and to a lesser extent in the proximal tibial metaphyses, and mild cupping proximal fibular metaphyses) (Figure [2](#F2){ref-type="fig"}C). A subsequent skeletal survey revealed generalized metaphyseal dysplasia involving the hip and wrist as well as the knee (Figures [2](#F2){ref-type="fig"}D,E). The spine showed generalized platyspondyly with irregular endplates. The posterior vertebral bodies were irregularly ossified (Figure [2](#F2){ref-type="fig"}B). These radiographic findings raised a suspicion of SPENCD. Laboratory data showed normal levels of serum calcium, phosphate, alkaline phosphatase, intact PTH, IGF-I, and thyroid function (Table S1 in Supplementary Material). No immunological abnormality was found, including normal levels of complements and no detectable autoantibodies. TRAP activity was undetectable (TRAP-5b \< 0.1 U/L). Bone mineral density on dual-energy x-ray absorptiometry was normal (L1--L4: 0.942 g/cm^2^). Brain CT of the patient showed bilateral calcifications of the basal ganglia (Figure [2](#F2){ref-type="fig"}F).

![**(A)** Clinical photographs. **(B)** Spinal radiograph showing generalized platyspondyly with irregular endplates and irregular ossifications in the posterior vertebral bodies. **(C)** Radiograph of the knees showing irregular and sclerotic splayed metaphyses of the distal femur, proximal tibia, and fibula. **(D,E)** Radiograph of the hip and wrist showing similar metaphyseal changes as the knee. **(F)** Brain CT showing bilateral calcification of the basal ganglia.](fendo-08-00157-g002){#F2}

Materials and Methods {#S3}
=====================

Genetic Analysis {#S3-1}
----------------

The genetic study of the patient was performed using a candidate gene approach with Sanger sequencing of the *ACP5* gene. A familial study was not performed because consent was not given.

INF Analysis {#S3-2}
------------

The expression of INF-stimulated genes in the patient's whole blood cells were measured by qPCR as described previously ([@B14]). Whole blood was collected into PAXgene tubes (PreAnalytix, Hombrechtikon, Swizerland) and frozen at −20°C until extraction using the manufacturer's protocol. Total RNA was extracted with a PAXgene RNA Blood kit (PreAnalytix) and reverse-transcribed to cDNA using an Omniscript RT kit (Qiagen, Hilden, Germany). Real time quantitative PCR was performed in triplicate using a 7900HT Fast Real-Time PCR system (Applied Biosystems, Waltham, MA, USA) and a kit for each INF-stimulated gene (*IFI27*, Hs01086370_m1; *IFIT1*, Hs00356631_g1; *RSAD2*, Hs01057264_m1; *SIGLEC1*, Hs00988063_m1; *ISG15*, Hs00192713_m1; *IFI44L*, Hs00199115_m1; *BACT*, Hs01060665_g1) (Life Technologies, Carlsbad, CA, USA). The expression levels were normalized to those of β-actin. Results are shown relative to a single calibrator (control 1).

Results {#S4}
=======

Identification of *ACP5* Mutations {#S4-1}
----------------------------------

The sequence analysis revealed novel *ACP5* mutations, a splice-site mutation (c.736-2 A\>C) and a nonsense mutation (c.526 C\>T; p.R176X) (Figures [3](#F3){ref-type="fig"}A,B). Neither 736-2 A\>C nor R176X were found in the NCBI, Ensembl, dbSNP, or ExAc databases.

![**(A,B)** Chromatograms showing the novel heterozygous mutations in *ACP5* identified in the patient; a splice-site mutation (c.736-2 A\>C) **(A)** and a nonsense mutation (c.526 C\>T; p.R176X) **(B)**. **(C)** Quantitative RT-PCR of INF-stimulated gene expression for, *IFI27, IFIT1, IFI44L, ISG15, RSAD2, SIGLEC1* in peripheral blood cells. The relative abundance of each transcript was normalized to the expression of β-actin. The experiment was performed in triplicate. Healthy control (*n* = 8); black circles, patient; red circles.](fendo-08-00157-g003){#F3}

Detection of INF Signature {#S4-2}
--------------------------

We identified marked upregulation of *IFI27, IFIT1, IFI44L, ISG15, RSAD2*, and *SIGLEC1* in the patient compared with healthy controls (*n* = 8) (Figure [3](#F3){ref-type="fig"}C).

Discussion {#S5}
==========

We report a boy with a typical SPENCD skeletal phenotype, who presented with postnatal short stature and brain calcifications. He has not developed immune dysregulation despite laboratory evidence of a type I INF signature. An IFN signature in SPENCD plays a major role in neurological and immune involvement. We summarized the clinical manifestations of 48 patients with SPENCD by reviewing previous reports, as presented in Table [1](#T1){ref-type="table"} ([@B1]--[@B9], [@B15]--[@B22]). Height ranged from −1.5 to −7.5 SD (only cases with SD notation were included). The common features that first prompt the seeking of medical attention include musculoskeletal symptoms (60.4%), such as short stature, short limbs, kyphoscoliosis, and bowlegs, followed by neurological symptoms (27.1%) and immune dysregulation (18.8%). On the other hand, Briggs et al. ([@B10]) reviewed 26 patients, including 12 previously reported patients, and identified that up to 50% initially presented with immune dysregulation, followed by musculoskeletal symptoms (46.2%) and neurological symptoms (23.1%). This difference between our review and Briggs' may represent the clinical diversity of SPENCD.

###### 

Literature review of SPENCD case reports.

  Author                Patient no.   Gender      At initial presentation                                            Growth failure                                                                       Neurological symptoms                                  Intracranial calcification   Immune dysregulation                                                   Reference                                                                                                                                        
  --------------------- ------------- ----------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------ ------------------------------------------------------ ---------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ----------
  Schorr et al.         Pt. 1         M           8 years                                                            Short stature                                                                        Yes                                                    No                           ND                                                                     No                                                                                                                                               ([@B1])
  Pt. 2                 M             5 years     Short stature                                                      Yes                                                                                  No                                                     ND                           Recurrent infections                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Gustavson et al.      Pt. 3         F           15 months                                                          Short stature                                                                        −7.5 SD at 16 years[^a^](#tfn1){ref-type="table-fn"}   No                           ND                                                                     ND                                                                                                                                               ([@B15])
  Pt. 4                 M             Birth       Short stature, short limbs, bowlegs                                −6.5 SD at 13 years[^a^](#tfn1){ref-type="table-fn"}                                 No                                                     ND                           ND                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Sauvegrain et al.     Pt. 5         F           16 years                                                           Short stature, short neck                                                            Yes                                                    No                           ND                                                                     ND                                                                                                                                               ([@B16])
  Pt. 6                 M             7 years     Short stature, Dev. delay                                          Yes                                                                                  Dev. delay                                             ND                           ND                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Chagnon et al.        Pt. 7         M           8 years                                                            Spastic quadriplegia                                                                 Yes                                                    Spasticity                   ND                                                                     ND                                                                                                                                               ([@B17])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Menger et al.         Pt. 8         M           Birth                                                              Short limbs                                                                          −6 SD at 12 years                                      Dev. delay                   ND                                                                     ND                                                                                                                                               ([@B18])
  Pt. 9                 M             Birth       Short limbs                                                        −6 SD at 9 years                                                                     Dev. delay                                             ND                           ND                                                                                                                                                                                                                      
  Pt. 10                M             4 months    Craniotabes, costochondral beading                                 −1.5 SD at 12 years                                                                  No                                                     ND                           ND                                                                                                                                                                                                                      
  Pt. 11                M             6 years     Short stature, spastic quadriplegia, kyphoscoliosis                −2 SD at 6 years                                                                     Dev. delay and spasticity                              ND                           ND                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Frydman et al.        Pt. 12        M           2.5 years                                                          Short stature                                                                        −2.5 SD at 11 years                                    No                           No                                                                     No                                                                                                                                               ([@B2])
  Pt. 13                F             2 years     Short stature                                                      −3.5 SD at 8 years                                                                   No                                                     No                           ND                                                                                                                                                                                                                      
  Pt. 14                M             10 years    ND                                                                 ND                                                                                   ND                                                     ND                           ND                                                                                                                                                                                                                      
  Pt. 15                M             15 years    Short stature, kyphosis, pectus carinatum, spastic quadriparesis   −3 SD at 15 years                                                                    Spasticity                                             Yes                          ND                                                                                                                                                                                                                      
  Pt. 16                M             2 years     Walking difficulties, spastic quadriparesis                        −4.4 SD at 8 years                                                                   Dev. delay and spasticity                              Yes                          ND                                                                                                                                                                                                                      
  Pt. 17                M             18 years    Lack of ejaculate                                                  −5.4 SD at 18 years                                                                  No                                                     Yes                          ND                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Robinson et al.       Pt. 18        M           11 years                                                           Short stature, joint pain                                                            \<3rd percentile at 19 years                           No                           ND                                                                     ND                                                                                                                                               ([@B19])
  Pt. 19                M             ND          ND                                                                 −5.5 SD at 86 years[^a^](#tfn1){ref-type="table-fn"}                                 ND                                                     ND                           ND                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Uhlmann et al.        Pt. 20        M           Birth                                                              Short stature, clubfoot, diastasis recti, low-set ears, simian creases, short neck   \<3rd percentile at 5 years                            No                           ND                                                                     No                                                                                                                                               ([@B20])
  Pt. 21                M             11 months   Short stature                                                      Yes                                                                                  No                                                     ND                           No                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Roifman and Melamed   Pt. 22        F           5 months                                                           Recurrent infections                                                                 \<3rd percentile at 18 years                           No                           ND                                                                     Recurrent infections, ITP, hypothyroidism, vitiligo                                                                                              ([@B3])
  Pt. 23                M             3 months    Recurrent infections                                               ND                                                                                   No                                                     No                           Recurrent infections, ITP, hypothyroidism                                                                                                                                                                               
  Pt. 24                M             3 years     Recurrent infections                                               Yes                                                                                  No                                                     ND                           Recurrent infections, ITP                                                                                                                                                                                               
  Pt. 25                M             Infancy     Recurrent infections                                               Around 10th percentile at 10 years                                                   No                                                     ND                           Recurrent infections, JRA, Crohn's disease, hypothyroidism, vitiligo                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Tuysuz et al.         Pt. 26        M           10 years                                                           Short stature                                                                        \<3rd percentile at 10 years                           No                           No                                                                     ND                                                                                                                                               ([@B4])
  Pt. 27                F             9 years     Short stature                                                      \<3rd--10th percentile at 21 years                                                   No                                                     No                           ND                                                                                                                                                                                                                      
  Pt. 28                M             7 years     Short stature, Dev. delay                                          \<3rd percentile at 7 years                                                          Dev. delay                                             Yes                          ND                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Bhargava et al.       Pt. 29        M           7 years                                                            Back pain, kyphosis                                                                  \<5th percentile at 13 years                           No                           ND                                                                     No                                                                                                                                               ([@B21])
  Pt. 30                F             Birth       Short stature                                                      \<5th percentile at 42 years                                                         ND                                                     ND                           ND                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Renella et al.        Pt. 31        M           3 years                                                            Short stature                                                                        \<3rd percentile at 3 years                            No                           No                                                                     SLE                                                                                                                                              ([@B5])
  Pt. 32                F             8 months    Leg stiffness                                                      \<3rd percentile at 3 years                                                          Dev. delay and spasticity                              Yes                          No                                                                                                                                                                                                                      
  Pt. 33                F             1 months    Short stature                                                      Yes                                                                                  No                                                     ND                           No                                                                                                                                                                                                                      
  Pt. 34                M             1 months    Leg stiffness                                                      \<3rd percentile at 18 years                                                         Dev. delay and spasticity                              Yes                          AIHA, FUO, ITP                                                                                                                                                                                                          
  Pt. 35                M             21 months   Leg stiffness, spastic paraparesis                                 Yes                                                                                  Dev. delay and spasticity                              ND                           ITP, AIHA                                                                                                                                                                                                               
  Pt. 36                M             10 years    Recurrent thrombocytopenia, recurrent fever of unknown origin      \<3rd percentile at 17 years                                                         Dev. delay and spasticity                              Yes                          ITP, FUO                                                                                                                                                                                                                
  Pt. 37                M             Childhood   Short stature                                                      Yes                                                                                  Spasticity                                             ND                           ND                                                                                                                                                                                                                      
  Pt. 38                F             11 years    Rheumatic fever with carditis, sydenham chorea                     \<3rd percentile at 12 years                                                         No                                                     ND                           Rheumatic fever                                                                                                                                                                                                         
  Pt. 39                M             8 months    Short stature                                                      \<3rd percentile at 7 years                                                          Dev. delay and spasticity                              No                           Inflammatory syndrome with hypogammaglobulinemia, AIHA                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Kulkarni et al.       Pt. 40        M           2 years                                                            Recurrent infections                                                                 \<5th percentile at 5 years                            No                           ND                                                                     Recurrent infections, compromised cellular immunity, SLE, ITP, JRA                                                                               ([@B6])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Navarro et al.        Pt. 41        F           3 years                                                            Febrile seizures                                                                     \<5th percentile at 23 years                           Dev. delay                   Yes                                                                    Sjögren syndrome, polymyositis, hypothyroidism, pancreatitis, autoimmune multifocal neuropathy, scleroderma                                      ([@B7])
  Pt. 42                M             2.5 years   Walking difficulties, skin rash                                    \<5th percentile at 10 years                                                         Spasticity                                             Yes                          Leukocytoclastic vasculitis, SLE                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Girschick et al.      Pt. 43        F           6 months                                                           Increased muscle tone of the lower limbs                                             Yes                                                    Spasticity                   No                                                                     AIHA, ITP, polyarthritis, hepatitis, nephritis, life-threatening hyperreactivity to viral infections as well as recurrent bacterial infections   ([@B8])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  de Bruin et al.       Pt. 44        F           13 years                                                           Short stature                                                                        −5.5 SD at 13 years                                    Dev. delay                   No                                                                     No                                                                                                                                               ([@B22])
  Pt. 45                M             8 years     Short stature                                                      −5.1 SD at 8 years                                                                   Dev. delay                                             No                           No                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Bilginer et al.       Pt. 46        M           5 years                                                            Short stature                                                                        \<3rd percentile at 5 years                            ND                           Yes                                                                    SLE (lupus nephritis)                                                                                                                            ([@B9])
  Pt. 47                F             16 years    Short stature, arthralgia, arthritis                               \<3rd percentile at 16 years                                                         ND                                                     Yes                          SLE (lupus nephritis), vitiligo                                                                                                                                                                                         
  Pt. 48                F             4.5 years   Leg stiffness, walking difficulties                                \<3rd percentile at 16 years                                                         Spasticity                                             Yes                          SLE (lupus nephritis)                                                                                                                                                                                                   

*M, male; F, female; ND, not described; Dev. delay, developmental delay; ITP, idiopathic thrombocytopenic purpura; JRA, juvenile rheumatoid arthritis; SLE, systemic lupus erythematosus; AIHA, autoimmune hemolytic anemia; FUO, fever of unknown origin*.

*^a^Described in Ref. ([@B10])*.

In the present case, postnatal growth failure was ameliorated with GH therapy; height increased from −2.89 SD to −1.04 SD over 3 years. The patient's IGF-I levels increased to within the normal range after commencing GH therapy (Figure S1 in Supplementary Material). In addition, GH therapy did not accelerate bone age; bone ages were 2.3 and 5.2 years at the chronological ages of 3 years 4 months and 6 years 11 months, respectively. These findings indicate the potential therapeutic benefit of GH to improve short stature in patients with SPENCD.

Two reports have been published describing three SPENCD patients who underwent GH therapy ([@B4], [@B10]). Briggs et al. ([@B10]) described two patients, including one patient with GHD who responded well to GH therapy. Tuysuz et al. ([@B4]) reported a 21-year-old woman with SPENCD who received GH therapy for 2 years from the age of 9 years such that she achieved a normal height (153 cm: 3--10 centile). It remains unclear whether a good response to GH therapy in these SPENCD patients is universal or not. Lack of TRAP leads to an increase in phosphorylated osteopontin, which is responsible for disordered endochondral ossification and reduced resorption of calcified cartilage matrix and primary spongiosa as a result of impaired adhesion, migration, and activation of osteoclasts ([@B11], [@B13], [@B23], [@B24]). Meanwhile, GH advances longitudinal bone growth directly by stimulating prechondrocyte differentiation, and indirectly by clonal expansion of differentiated chondrocytes through upregulation of IGF-I ([@B25]--[@B29]). Moreover, GH stimulates resorption of cartilage matrix and immature bone through both its direct and indirect actions on osteoclast formation and differentiation and through indirect activation of mature osteoclasts *via* osteoblasts. Upregulation of IGF-I associated with GH therapy also supports osteoclastic activities ([@B30], [@B31]). These effects of GH may efficiently counteract the negative effects on endochondral bone growth in SPENCD.

Growth hormone therapy is associated with adverse risks in some patients, such as femoral head necrosis, slipped capital femoral epiphysis, exostosis, and the progression of bone deformities, particularly spinal deformities, such as scoliosis. We have not observed any obvious adverse events associated with GH therapy in the present case up to this time. However, because only 3 years has passed since the patient commenced GH therapy, the patient will require regular follow-up to evaluate the potential long-term effects of GH therapy. In addition, there are some other limitations in our study. First, the patient has partial GHD as well as SPENCD, and therefore the potential benefit of GH therapy for short stature in patients with SPENCD might be overestimated. Second, the patient is 6 years old and is too young to evaluate the effect of GH therapy on his final height. Despite these limitations, however, the improvement in growth velocity found in the present case is encouraging and may suggest the potential therapeutic benefit of GH in patients with SPENCD.

Concluding Remarks {#S6}
==================

This case report described the treatment of a patient who presented progressive growth failure associated with SPENCD and partial GHD. After commencing GH therapy, the patient's height SD score improved from −2.89 SD to −1.04 SD over 3 years without accelerating the bone age. Considering the improvement in growth velocity in the present case, it is reasonable to suggest that GH therapy is warranted in patients with SPENCD, at least for those who show evidence of a partial GHD. Further studies are recommended to evaluate the benefit of GH therapy in improving the height of patients with SPENCD, even in the absence of GHD.
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